Editorial: Stent thrombosis: Who's guilty?

European Heart Journal

Volumn 30, Issue 22, 2009, Pages 2685-2688

  Montalescot, Gilles ^a   Hulot, Jean Sébastien ^b   Collet, Jean Philippe ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DEXTRAN; PRASUGREL; TICLOPIDINE; WARFARIN; ANTITHROMBOCYTIC AGENT; CYP2C19 PROTEIN, HUMAN; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; THIOPHENE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; BARE METAL STENT; CLINICAL DECISION MAKING; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG ELUTING STENT; EDITORIAL; HUMAN; PATIENT COMPLIANCE; PHARMACOGENETICS; PRIORITY JOURNAL; RISK ASSESSMENT; STENT THROMBOSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS PREVENTION; TREATMENT WITHDRAWAL; BLOOD VESSEL PROSTHESIS; CARDIOLOGY; CLINICAL COMPETENCE; GENETICS; GRAFT OCCLUSION; NOTE; RISK FACTOR; STANDARD; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ARYL HYDROCARBON HYDROXYLASES; BLOOD VESSEL PROSTHESIS; CARDIOLOGY; CLINICAL COMPETENCE; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THIOPHENES; TICLOPIDINE;

EID: 72949116367     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp436     Document Type: Editorial

References (27)

1. van Werkum JW, Heestermans AA, Zomer AC, Kelder JC, Suttorp MJ, Rensing BJ, Koolen JJ, Brueren BR, Dambrink JH, Hautvast RW, Verheugt FW, ten Berg JM. Predictors of coronary stent thrombosis: the Dutch Stent Thrombosis Registry. J Am Coll Cardiol 2009;53:1399-1409.
2. Schulz S, Schuster T, Mehilli J, Byrne RA, Ellert J, Massberg S, Goedel J, Bruskina O, Ulm K, Schömig A, Kastrati A. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopido-grel therapy over a 4-year period. Eur Heart J 2009;30:2714-2721. First published on 11 July 2009. doi:10.1093/eurheartj/ ehp275.
3. Eisenberg MJ, Richard PR, Libersan D, Filion KB. Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents. Circulation 2009; 119:1634-1642.
4. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, White HD. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-1452.
5. Collet JP, Montalescot G, Blanchet B, Tanguy ML, Golmard JL, Choussat R, Beygui F, Payot L, Vignolles N, Metzger JP, Thomas D. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 2004;110:2361-2367.
6. Collet JP, Montalescot G, Steg PG, Steinhubl SR, Fox KAA, Hu T, Johnston SC, Hamm CV, Bhatt DL, Topol EJ. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009;102:485-496.
7. Lüscher T, Steffel J, Eberli FR, M J, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1068.
8. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Möckel M, Ochala A, Kellock A, Parise H, Mehran R, HORIZONS-AMI Trial Investigators. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009;360:1946-1959.
9. James SK, Stenestrand U, Lindbäck J, Carlsson J, Scherstén F, Nilsson T, Wallentin L, Lagerqvist B; SCAAR Study Group. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med 2009;360: 1933-1945.
10. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol Intervention 2009;53:849-856.
11. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini G. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009;119:237-242.
12. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ. Cytochrome P450 2C19 681G. A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008;51: 1925-1934.
13. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008;29:992-1000.
14. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49: 2312-2317.
15. Michelson AD, Frelinger AL, Braunwald E, Downey WE, Angiolillo DJ, Xenopoulos NP, Jakubowski JA, Li Y, Murphy SA, Qin J, McCabe CH, Antman EM, Wiviott SD. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 Trial. Eur Heart J 2009;30: 1753-1763.
16. Montalescot G, Sideris G, Cohen A, Meuleman C, Bal-Dit-Sollier C, Collet JP, Henry P, Lim P, Marshall D, Drouet D, on behalf of The ACAPULCO Investigators. Prasugrel 10 mg provides greater platelet inhibition than clopidogrel 900/150 mg in UA/NSTEMI ACS-the ACAPULCO study. Eur Heart J 2008; 29(Suppl):746 (Abstract 4408).
17. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myo-cardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-731.
18. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FW, Goodman SG, Corbalan R, Purdy DA, Murphy SA, McCabe CH, Antman EM, TRITON-TIMI 38 Investigators. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008;118: 1626-1636.
19. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, Steg G, Ferrières J, Danchin N, Becquemont L, for the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009;360:363-375.
20. Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, Morath T, Schömig A, Kastrati A, von Beckerath N. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009;30:916-922.
21. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360:354-362.
22. Gurbel PA, Bliden KP, Ryan K, Herzog W, Antonino MJ, Tantry US, Shuldiner AR. Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence. J Am Coll Cardiol Intervention 2009;10(Suppl 1)(I2 Summit (symposium 2404)).
23. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano G, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myo-cardial infarction: a cohort study. Lancet 2009;373:309-317.
24. Anderson JL, Mower CP, Horne BD, Muhlestein JB, Park JJ, Bair TL, Carlquist JF. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel. J Am Coll Cardiol 2009;53: 2903-2908.
25. Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009;103:806-811.
26. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed 1997;53: 187-190. (Pubitemid 27305437)
27. Pena A, Collet JP, Hulot JS, Silvain J, Barthélémy O, Beygui F, Funck-Brentano C, Gilles Montalescot. Can we override clopidogrel resistance? Circulation 2009;119: 2854-2857